Biotech's Next Big Thing: Aegerion
Aegerion and its cholesterol drug will be biotech's big thing in the coming week, says Adam Feuerstein, Sr. Columnist for TheStreet.
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.
